CN Patent

CN113811333B — 靶向抗癌核激素受体的化合物

Assigned to Novelson Biological Co ltd · Expires 2024-03-12 · 2y expired

What this patent protects

本公开涉及衍生自核类固醇受体结合剂的抗癌化合物、涉及含有其的产品以及涉及其使用和制备方法。

USPTO Abstract

本公开涉及衍生自核类固醇受体结合剂的抗癌化合物、涉及含有其的产品以及涉及其使用和制备方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN113811333B
Jurisdiction
CN
Classification
—
Expires
2024-03-12
Drug substance claim
No
Drug product claim
No
Assignee
Novelson Biological Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.